{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:04:09Z","timestamp":1792195449418,"version":"4.4.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":296,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims and Background<\/jats:title>\n                    <jats:p>Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR-CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression. The study aims to assess delays in diagnosis in ATTR-CM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with ATTR-CM receiving transthyretin stabilizer therapy at the West German Amyloidosis Center (01\/2018\u201312\/2023) were included. Clinical, laboratory, and imaging data were analysed. Diagnostic timelines were compared across two periods (2018\u20132020 and 2021\u20132023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After screening 254 patients, 154 were included in the analysis. ATTRwt was the most common form (96.8%). The median age was 80 (76\u201383) years, 87% were male and 46.6% were NYHA class \u2265III. Time to diagnosis decreased from 398 to 277 days in the second period (P &amp;lt; 0.001). The median duration from diagnosis to stabilizer therapy was 84 (44\u2013160) days, reducing from 111 (55\u2013237) days in the first period to 57 (36\u2013102) days in the second period (P &amp;lt; 0.001). Patients diagnosed in the first period had lower LVEF (P &amp;lt; 0.001) and more advanced NAC stages (P = 0.004). More women were diagnosed in the second period (P = 0.010).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ATTR-CM is associated with diagnostic delays from initial suspicion to therapy initiation. While diagnostic and treatment timelines have improved, enhanced awareness, supraregional networks, specialized centres and focused education are essential to improve diagnosis and outcomes. Increasing awareness has led to patients being diagnosed at earlier disease stages, underscoring the potential to positively impact patient prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15311","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T01:54:29Z","timestamp":1745891669000},"page":"2969-2975","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis"],"prefix":"10.1093","volume":"12","author":[{"given":"Julia","family":"Vogel","sequence":"first","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]},{"name":"West German Amyloidosis Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Jura","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]},{"name":"West German Amyloidosis Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Settelmeier","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]},{"name":"West German Amyloidosis Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Buehning","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lerchner","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carpinteiro","sequence":"additional","affiliation":[{"name":"West German Amyloidosis Center, University Hospital Essen , Essen ,","place":["Germany"]},{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]},{"name":"West German Amyloidosis Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen , Essen ,","place":["Germany"]},{"name":"West German Amyloidosis Center, University Hospital Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2026021804082775100_ehf215311-bib-0001","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804082775100_ehf215311-bib-0002","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021804082775100_ehf215311-bib-0003","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026021804082775100_ehf215311-bib-0004","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"2026021804082775100_ehf215311-bib-0005","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021804082775100_ehf215311-bib-0006","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804082775100_ehf215311-bib-0007","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11897-024-00669-7","article-title":"Current therapies and future horizons in cardiac amyloidosis treatment","volume":"21","author":"Vogel","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"2026021804082775100_ehf215311-bib-0008","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804082775100_ehf215311-bib-0009","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis - a clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026021804082775100_ehf215311-bib-0010","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"2026021804082775100_ehf215311-bib-0011","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/ehf2.15126","article-title":"Real-world characteristics and treatment of cardiac transthyretin amyloidosis: a multicentre, observational study","volume":"12","author":"Nies","year":"2024","journal-title":"ESC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/4\/2969\/66953949\/eschf_12_4_2969.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/4\/2969\/66953949\/eschf_12_4_2969.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:08:34Z","timestamp":1771405714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/4\/2969\/8488049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,28]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15311","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"2024-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}